Longevity & AgingInflammation Drives a Distinct Subtype of Depression With Unique Symptoms and Treatment Response
Dr. Andrew Miller of Emory University presents compelling evidence that roughly 25% of people with major depression have chronically elevated inflammatory markers—such as CRP, TNF, IL-1β, and IL-6—that drive a distinct clinical subtype. This inflammatory subtype is characterized by anhedonia, fatigue, psychomotor slowing, and sleep/appetite disruption, and is associated with poor response to SSRIs but potentially better response to catecholaminergic agents, ketamine, ECT, and anti-inflammatory treatments like infliximab. Mechanistically, inflammation disrupts dopamine and glutamate signaling in basal ganglia and corticostriatal reward circuits. The paper argues that recognizing this subtype enables precision psychiatry: matching patients to biologically targeted therapies rather than one-size-fits-all antidepressants.
